Verrica Pharmaceuticals Advances Phase 3 Trial for Common Warts Treatment — Verrica Pharmaceuticals Inc.

Event summary

First U.S. patient dosed in COVE-3 Phase 3 trial of YCANTH (VP-102) for common warts on June 22, 2026.
Torii Pharmaceuticals dosed the first Japanese patient in the same trial last week.
Phase 3 program includes two double-blind, randomized, vehicle-controlled studies with up to four applications of VP-102/TO-208 every 21 days.
COVE-2 trial is already over 50% enrolled; COVE-4 long-term follow-up study also enrolling patients.

The big picture

Verrica Pharmaceuticals is advancing its YCANTH (VP-102) treatment into a second pivotal Phase 3 trial for common warts, a condition with no FDA-approved therapies. The company's partnership with Torii Pharmaceuticals, backed by Shionogi & Co., Ltd., underscores the global strategic importance of this program. If successful, YCANTH could address a multibillion-dollar market opportunity in dermatology.

What we're watching

Regulatory Pathway: Whether the Phase 3 data will support marketing approval in both the U.S. and Japan.
Commercial Potential: The scale of the unmet need for common warts treatment, with an estimated 22 million patients in the U.S. alone.
Execution Risk: The pace at which Verrica and Torii can complete enrollment and generate pivotal data from the Phase 3 program.